Niche focus Target Neurological Therapies: PeriphaGen operates in a specialized area of peripheral nerve gene therapy with a clear lead product for CIPN, presenting a focused opportunity to align with oncology and neurology adjacent service providers, CROs, and potential pharma partners seeking niche CNS/nerve-targeted treatments.

Clinical value High-value collaboration potential: The NET platform promises targeted expression with reduced systemic adverse effects, which can be leveraged in partnerships for co-development, licensing, or sponsored research with larger Biotech firms seeking differentiated neurological solutions.

Funding leverage Early-stage funding signals: With modest revenue and recent funding, there is room to pursue strategic partnerships, grant support, or milestone-driven deals with mid-to-large pharma players looking to expand their rare disease and oncology supportive care portfolios.

Intellectual property IP and litigation angle: Past legal activity over gene therapy technology indicates valuable IP assets and potential for diligence-driven partnerships, licensing conversations, or cross-licensing discussions with companies active in gene therapy.

Speed-to-market Small team agility and CRO-ready: The lean headcount suggests fast decision-making and potential for streamlined external collaborations, CRO engagements, and bundled services with technology partners to accelerate development timelines.